COMP <GO>
ANIP vs MRK // REVENUE GROWTH (YOY)
ANI Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ANIP 5
— MRK 6
▲ REVENUE GROWTH (YOY) LEADER: ANIP
LAST: $72.00 (-1.59%) • MKT CAP: $1.68B
revenue-growth
43.80%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
revenue-growth
1.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANIP VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANIP | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.00% | 20.70% | -4.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.7x | 15.3x | -1.60 | ANIP | /valuation <GO> |
| Free Cash Flow Yield | 10.20% | 3.42% | +6.78 | ANIP | /fcf-yield <GO> |
| Operating Margin | 12.60% | 34.30% | -21.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | 8.80% | 28.10% | -19.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 43.80% | 1.30% | +42.50 | ANIP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.07% | 2.26% | -2.19 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.36 | 5.19 | -2.83 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ANIP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.7 | 51.7 | 0.00 | TIE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.1x | 18.4x | -0.30 | ANIP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.68B | $361.02B | -$359.34B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANIP REV | MRK REV | ANIP GROSS % | MRK GROSS % | ANIP FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $883.4M | $65.01B | — | 74.8% | $171.4M | $12.36B |
| FY 2024 | $614.4M | $64.17B | — | 76.3% | $47.8M | $18.10B |
| FY 2023 | $486.8M | $60.12B | — | — | $119.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANIP // BETA —
MRK // BETA 0.92